GUD (GUD) News
Follow GUD (GUD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Kyowa Kirin, Knight Therapeutics Enter Distribution Deal For POTELIGEO In Latin America
OTTAWA (dpa-AFX) - Tuesday, Kyowa Kirin (4151.T) said it entered into an exclusive distribution agreement with Knight Therapeutics (GUD.TO) for POTELIGEO (mogamulizumab) in select Latin American countries.Under the agree
NEWS | Sep 29, 2026, 01:18 PM UTC
L
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX:GUD) for
NEWS | Sep 29, 2026, 12:00 PM UTC
L
Knight Therapeutics Inc. (GUD) Wins Exclusive Poteligeo Distribution in Key LatAm Markets
Knight Therapeutics signed an exclusive agreement with Kyowa Kirin International to seek approvals and commercialize mogamulizumab (Poteligeo) in Brazil, Mexico, Colombia and Argentina.Material DetailsContext by AI Analy
NEWS | Sep 29, 2026, 11:33 AM UTC
L
Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies
MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. TSX:GUD (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Gro
NEWS | Sep 25, 2026, 01:58 PM UTC
L
Knight Therapeutics Inc. (TSX:GUD) NDS for GEMTESA Accepted by Health Canada
Knight Therapeutics said Health Canada accepted its New Drug Submission for GEMTESA for overactive bladder, including adult males on BPH pharmacotherapy.Material DetailsContext by AI AnalystThis is an early regulatory mi
NEWS | Sep 15, 2026, 11:34 AM UTC
L
Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada
MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") TSX:GUD, a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron), pr
NEWS | Sep 15, 2026, 11:33 AM UTC
M
Knight Therapeutics receives Colombia regulatory approval for Tavalisse
Knight Therapeutics said regulatory approval was granted for Tavalisse® in Colombia.
EQUITY | Sep 01, 2026, 10:04 PM UTC
L
Knight Therapeutics files supplemental Brazil submission for Minjuvi
Knight Therapeutics announced a supplemental regulatory submission for Minjuvi in Brazil.
EQUITY | Aug 27, 2026, 10:07 PM UTC